Mavenir Announces R & D Center of Excellence Focused on Artificial Intelligence/Machine Learning Signaling Security
Mavenir, the leader in accelerating and redefining network transformation for Service Providers, has today announced its R&D centre of excellence in Brno, Czech Republic focused on Artificial Intelligence/machine learning signaling security solutions. Mavenir’s solution provides the most advanced signaling monitoring, active filtering and powerful analytics to ensure networks remain fully functional and operational, while ensuring customers stay protected when using network services.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170608005425/en/
Network Security (Graphic: Business Wire)
Although Signaling System 7 (SS7) has been widely used for decades, hackers only began exploiting vulnerabilities in recent years and operators are now ramping up the signaling security in their networks. This extended security focus comes as an operator in Germany confirmed that some of its customers had their bank accounts drained last month, through SS7 signaling fraud.
Mavenir has deep expertise in signaling security capabilities, with Security Gateways (SeGWs) and Diameter Edge Agents (DEAs), Signaling Transfer Points (STPs) and Diameter Routing Agents (DRAs) to ensure the most advanced edge and core network signaling protection available.
Mavenir also provides security auditing services. Results of a recent SS7 audit of more than thirty networks indicated that every network has some vulnerability in SS7. The exploits observed during auditing enable attacks that range from call and message eavesdropping to denial of service and fraud.
“Operators are seeking to mitigate against network attacks and vulnerabilities, in addition to accelerating their efforts to implement firewall solutions for the next generation of networks,” said Pardeep Kohli, President and CEO at Mavenir. “Our network security solution uses Artificial Intelligence/machine learning and analytics for SS7 Security, Diameter Security, SIP Security, and Network Optimization.”
Kohli continued, “Legacy SS7 technology may eventually be replaced by Diameter or SIP, but SS7 will be around for some time and therefore must be secured. Continuing to address security flaws in signaling protocols with an optimal, multi-layer solution means that operators can shield enterprises and subscribers while ensuring their services remain fully available and generating revenue.”
Mavenir’s network security solutions are deployed in multiple operator networks across North America, EMEA and APAC regions. Artificial intelligence and machine learning power Mavenir’s world leading messaging SIM-box, grey-route and fraud detection capability offered by our SpamShield product.
Want to learn more? Mavenir will be exhibiting (Booth 5G565) and speaking at Network Security and 5G World in Jun 13-15th in London.
About Mavenir Systems, Inc. | Mavenir
Mavenir is the leader in accelerating and redefining network transformation for Service Providers, by offering a comprehensive product portfolio across every layer of the network infrastructure stack. From 5G application/service layers to packet core and RAN – Mavenir leads the way in evolved, cloud-native networking solutions enabling innovative and secure experiences for end users.
Through its industry first VoLTE, VoWiFi, Advanced Messaging (RCS), Multi ID, Visual Voicemail and Cloud RAN solutions, and serving 350+ CSPs across 3.5 billion subscribers, Mavenir’s platform enables Service Providers to successfully deliver next generation vision today and realize new revenue streams and operational efficiencies. www.mavenir.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170608005425/en/
Contact information
Media:
Matter for Mavenir
Nicole Brooks, 971-246-7898
mavenir@matternow.com
or
Hotwire
PR
Hannah Lock / Dom Conolly
mavenir@hotwirepr.com
+44
(0) 207 608 2500
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Receives CHMP Positive Opinion for ALYFTREK ® , a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis28.4.2025 09:03:00 EEST | Press release
Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Our goal has always been to serially innovate to help people with cystic fibrosis live healthier and longer lives. If approved, this new medicine would be indicated for people with CF ages 6 years and older with at least one non-class I mutation, meaning more patients would be eligible for a medicine that gets them closer to normal levels of sweat chloride,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. “CFTR modulators have already revolutionized the way we treat CF and I am encoura
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 08:02:00 EEST | Press release
Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization and further development of pridopidine in Europe and other select markets. Pridopidine is a potent and highly selective, orally administered sigma-1 receptor (S1R) agonist designed to regulate key neuroprotective mechanisms often impaired in neurodegenerative diseases such as HD and ALS. Under the terms of the agreement, Prilenia will receive an upfront payment of approximately €80 million plus up to €45 million in near-term development, regulatory, and commercial milestones. The total deal is valued at up to approximately €500 million in upfront and total milestone payments. In addition, Prilenia will receive tiered double-digit royalties on
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 08:00:00 EEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 12:36:00 EEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 20:00:00 EEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom